ArticleEMBO molecular medicine2017

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

Jörg T Regula et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.